Cargando…

Intrathecal Therapy for Chronic Pain: A Review of Morphine and Ziconotide as Firstline Options

OBJECTIVES: To evaluate the evidence for morphine and ziconotide as firstline intrathecal (IT) analgesia agents for patients with chronic pain. METHODS: Medline was searched (through July 2017) for “ziconotide” or “morphine” AND “intrathecal” AND “chronic pain,” with results limited to studies in hu...

Descripción completa

Detalles Bibliográficos
Autores principales: Deer, Timothy R, Pope, Jason E, Hanes, Michael C, McDowell, Gladstone C
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6442748/
https://www.ncbi.nlm.nih.gov/pubmed/30137539
http://dx.doi.org/10.1093/pm/pny132
_version_ 1783407749126684672
author Deer, Timothy R
Pope, Jason E
Hanes, Michael C
McDowell, Gladstone C
author_facet Deer, Timothy R
Pope, Jason E
Hanes, Michael C
McDowell, Gladstone C
author_sort Deer, Timothy R
collection PubMed
description OBJECTIVES: To evaluate the evidence for morphine and ziconotide as firstline intrathecal (IT) analgesia agents for patients with chronic pain. METHODS: Medline was searched (through July 2017) for “ziconotide” or “morphine” AND “intrathecal” AND “chronic pain,” with results limited to studies in human populations. RESULTS: The literature supports the use of morphine (based primarily on noncontrolled, prospective, and retrospective studies) and ziconotide (based on randomized controlled trials and prospective observational studies) as first-choice IT therapies. The 2016 Polyanalgesic Consensus Conference (PACC) guidelines recommended both morphine and ziconotide as firstline IT monotherapy for localized and diffuse chronic pain of cancer-related and non–cancer-related etiologies; however, one consensus point emphasized ziconotide use, unless contraindicated, as firstline IT therapy in patients with chronic non–cancer-related pain. Initial IT therapy choice should take into consideration individual patient characteristics (e.g., pain location, response to previous therapies, comorbid medical conditions, psychiatric history). Trialing is recommended to assess medication efficacy and tolerability. For both morphine and ziconotide, the PACC guidelines recommend conservative initial dosing strategies. Due to its narrow therapeutic window, ziconotide requires careful dose titration. Ziconotide is contraindicated in patients with a history of psychosis. IT morphine administration may be associated with serious side effects (e.g., respiratory depression, catheter tip granuloma), require dose increases, and cause dependence over time. CONCLUSION: Based on the available evidence, morphine and ziconotide are recommended as firstline IT monotherapy for cancer-related and non–cancer-related pain. The choice of first-in-pump therapy should take into consideration patient characteristics and the advantages and disadvantages of each medication.
format Online
Article
Text
id pubmed-6442748
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher Oxford University Press
record_format MEDLINE/PubMed
spelling pubmed-64427482019-04-04 Intrathecal Therapy for Chronic Pain: A Review of Morphine and Ziconotide as Firstline Options Deer, Timothy R Pope, Jason E Hanes, Michael C McDowell, Gladstone C Pain Med NEUROMODULATION & INTERVENTIONAL SECTION OBJECTIVES: To evaluate the evidence for morphine and ziconotide as firstline intrathecal (IT) analgesia agents for patients with chronic pain. METHODS: Medline was searched (through July 2017) for “ziconotide” or “morphine” AND “intrathecal” AND “chronic pain,” with results limited to studies in human populations. RESULTS: The literature supports the use of morphine (based primarily on noncontrolled, prospective, and retrospective studies) and ziconotide (based on randomized controlled trials and prospective observational studies) as first-choice IT therapies. The 2016 Polyanalgesic Consensus Conference (PACC) guidelines recommended both morphine and ziconotide as firstline IT monotherapy for localized and diffuse chronic pain of cancer-related and non–cancer-related etiologies; however, one consensus point emphasized ziconotide use, unless contraindicated, as firstline IT therapy in patients with chronic non–cancer-related pain. Initial IT therapy choice should take into consideration individual patient characteristics (e.g., pain location, response to previous therapies, comorbid medical conditions, psychiatric history). Trialing is recommended to assess medication efficacy and tolerability. For both morphine and ziconotide, the PACC guidelines recommend conservative initial dosing strategies. Due to its narrow therapeutic window, ziconotide requires careful dose titration. Ziconotide is contraindicated in patients with a history of psychosis. IT morphine administration may be associated with serious side effects (e.g., respiratory depression, catheter tip granuloma), require dose increases, and cause dependence over time. CONCLUSION: Based on the available evidence, morphine and ziconotide are recommended as firstline IT monotherapy for cancer-related and non–cancer-related pain. The choice of first-in-pump therapy should take into consideration patient characteristics and the advantages and disadvantages of each medication. Oxford University Press 2019-04 2018-08-22 /pmc/articles/PMC6442748/ /pubmed/30137539 http://dx.doi.org/10.1093/pm/pny132 Text en © 2018 American Academy of Pain Medicine. http://creativecommons.org/licenses/by-nc/4.0/ This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited. For commercial re-use, please contact journals.permissions@oup.com
spellingShingle NEUROMODULATION & INTERVENTIONAL SECTION
Deer, Timothy R
Pope, Jason E
Hanes, Michael C
McDowell, Gladstone C
Intrathecal Therapy for Chronic Pain: A Review of Morphine and Ziconotide as Firstline Options
title Intrathecal Therapy for Chronic Pain: A Review of Morphine and Ziconotide as Firstline Options
title_full Intrathecal Therapy for Chronic Pain: A Review of Morphine and Ziconotide as Firstline Options
title_fullStr Intrathecal Therapy for Chronic Pain: A Review of Morphine and Ziconotide as Firstline Options
title_full_unstemmed Intrathecal Therapy for Chronic Pain: A Review of Morphine and Ziconotide as Firstline Options
title_short Intrathecal Therapy for Chronic Pain: A Review of Morphine and Ziconotide as Firstline Options
title_sort intrathecal therapy for chronic pain: a review of morphine and ziconotide as firstline options
topic NEUROMODULATION & INTERVENTIONAL SECTION
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6442748/
https://www.ncbi.nlm.nih.gov/pubmed/30137539
http://dx.doi.org/10.1093/pm/pny132
work_keys_str_mv AT deertimothyr intrathecaltherapyforchronicpainareviewofmorphineandziconotideasfirstlineoptions
AT popejasone intrathecaltherapyforchronicpainareviewofmorphineandziconotideasfirstlineoptions
AT hanesmichaelc intrathecaltherapyforchronicpainareviewofmorphineandziconotideasfirstlineoptions
AT mcdowellgladstonec intrathecaltherapyforchronicpainareviewofmorphineandziconotideasfirstlineoptions